| |AUGUST 20269WILL SALMONELLA EVOLVE INTO NEXT BIG GLOBAL HEALTH CONCERN?INDIA TIGHTENS THE NOOSE ON PHARMA COMPANIES FAKING APPROVAL DATA AUROBINDO JOINS INDIA'S BIOLOGICS LEADERS WITH USD 200 M GOALSINDIA PUSHES NON-ANIMAL TESTING TO TRANSFORM DRUG RESEARCHNOVO NORDISK TIGHTENS GRIP ON SEMAGLUTIDE PATENT IN EUGlobal health concern intensifies as the latest Salmonella outbreak in the United States exposes the growing risks linked to foodborne infections. Health authorities confirmed 345 cases across 27 states, with 36 hospitalizations tied to contaminated jalapeno peppers imported from Mexico. This global health issue gains urgency as multiple outbreaks in 2026 involve eggs, fresh produce, and packaged foods across regions. Salmonella already causes about 1.35 million infections annually in the United States, highlighting its scale and impact. These repeated incidents are pushing regulators and policymakers to treat Salmonella as a serious global health challenge. POPharma companies in India face a stricter test as the Centre amends the Drugs Rules. This is to debar companies that submit fake or fabricated data during drug approval applications. The Ministry of Health and Family Welfare notifies these changes, Aurobindo Pharma sets its sights on a USD 200 million revenue target from its TheraNym biologics venture by 2032. The company inaugurated TheraNym, one of India's largest dedicated biologics contract manufacturing organizations, in Telangana. Aurobindo now joins established Indian biologics leaders like Biocon, Dr Reddy's, and Zydus in a fast-growing biosimilars race worth billions.This bold move intensifies pharma competition India has rarely witnessed, as biosimilars companies chase shares in a global biologics market set to expand through 2035. Aurobindo builds TheraNym as a dedicated biologics CMO and ranks it among India's largest facilities of its kind. Telangana ministers D. Sridhar Babu and Damodar Raja Narasimha attend the inauguration, and MSD anchors the plant as its first major customer. PODrug research in India is undergoing a major shift as the government accelerates support for non-animal testing methods. Policymakers are actively promoting advanced technologies such as organ-on-chip systems, organoids, and artificial intelligence to improve drug research outcomes.This strategic move aligns with global scientific trends and strengthens India's drug discovery capabilities. Government-backed initiatives, regulatory reforms, and The Semaglutide patent stands at the center of a major Novo Nordisk legal case as the company strengthens pharma patent enforcement across Europe. Novo Nordisk secured a Dutch court injunction against a pharmacy firm that produced a compounded semaglutide nasal spray without authorization. This reinforces Wegovy patent protection and intensifies drug IP litigation in the region. The court ordered an immediate halt to production and sales, removal of listings, and disclosure of supply chains linked to the infringing product. This Semaglutide patent ruling highlights how aggressively innovators now defend blockbuster GLP-1 drugs that generate billions in global revenue. POinstitutional collaborations are driving the adoption of alternative testing methods. This positions India as a leader in ethical, efficient, and human-relevant drug research across pharmaceutical innovation and safety evaluation frameworks. POaiming to empower authorities to reject applications and cancel licenses.This move follows a draft notification the ministry issued on October 28, 2025, after the Drug Technical Advisory Board flagged the issue. Drug manufacturer penalties and pharmaceutical regulatory misconduct finally meet a direct regulatory response instead of criminal complaints. PO
< Page 8 | Page 10 >